It’s rare to find a clinician who raves about their organization’s electronic health record. Nearly every provider needs an EHR, but few are satisfied with their system — often due to its difficulty of…
Continue Reading
In our new episode, we talk about Medtech, software development for medical devices, and regulations. Wessel Kooyman is a consulting expert who has lots to share with our audience. We started our interview by…
Continue Reading
Patients whose blood cancer advances after initial treatments have one last therapeutic option: the engineering of their immune cells into a living medicine. But cancer is crafty and it often finds a way to…
Continue Reading
By Mark Melchionna March 03, 2023 – Published in the Journal of the American Heart Association, a new study found that among US military veterans hospitalized for cardiac issues, those who took…
Continue Reading
Hybrid fertility and reproductive care company Kindbody scored a whopping $100 million from life sciences investment firm Perceptive Advisors, bringing its total raise to $290 million and its valuation to $1.8 billion. WHAT ITS FOR
Kindbody…
The Federal Trade Commission has started cracking down on digital health companies for allegedly sharing consumers’ health data for advertising purposes. Last month, the agency said GoodRx had shared personal health information with third parties…
Continue Reading
Top News
VA Deputy Secretary Donald Remy, JD, who oversees the VA’s Oracle Cerner implementation and other initiatives as its equivalent to COO, resigns as of April 1.
Remy’s departure follows that of VA EHR…
By Sarai Rodriguez March 02, 2023 – Healthcare data breaches remain a persistent problem for healthcare organizations, with no signs of slowing down. Despite increased efforts to strengthen cybersecurity, the industry remains…
Continue Reading
The Federal Trade Commission has fined online therapy company BetterHelp $7.8 million for allegedly sharing consumer data with third parties like Facebook and Snapchat for advertising purposes.The proposed order — the second recent action…
Continue Reading
MorphoSys, a company whose research has yielded programs placed with big pharmaceutical companies and upstart biotechs, is stopping all preclinical work to focus on cancer, particularly a late-stage drug candidate it acquired in a…
Continue Reading
